Retigabine modified releaseAlternative Names: Retigabine ER; Retigabine extended release; Retigabine MR; Retigabine sustained release; Retigabine XR
Latest Information Update: 01 Dec 2015
At a glance
- Originator Meda
- Developer GlaxoSmithKline; Valeant Pharmaceuticals International
- Class Antiepileptic drugs; Carbamates; Fluorobenzenes; Phenylenediamines; Small molecules
- Mechanism of Action GABA A receptor agonists; KCNQ potassium channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Partial epilepsies